2018/2019 ICD-10-CM Diagnosis Code R78.81. Bacteremia. R78.81 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2018/2019 edition of ICD-10-CM R78.81 became effective on October 1, 2018.
BACTROBAN nasal ointment is a white to off-white ointment that contains mupirocin calcium (equivalent to 2% mupirocin free acid). BACTROBAN nasal ointment, 2% is supplied in single-use 1‑gram tubes. NDC 0029-1526-03 Single-use 1‑gram tube in Package of 10: NDC 0029-1526-11.
BACTROBAN nasal ointment is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of BACTROBAN nasal ointment.
Diagnosis Index entries containing back-references to R78.81: 1 Bacteremia R78.81 2 Findings, abnormal, inconclusive, without diagnosis - see also Abnormal culture blood R78.81 3 Positive culture (nonspecific) blood R78.81
Treats certain skin infections and kills bacteria in the nose. Compared to over-the-counter first aid topical antibiotics, Bactroban (mupirocin) can kill a larger variety of bacteria and is a good alternative if you're allergic to certain ingredients in OTC products.
It is an antibiotic. It works by stopping the growth of certain bacteria. Mupirocin is available under the following different brand names: Bactroban, Bactroban Nasal, and Centany.
ICD-10 Code for Encounter for issue of other medical certificate- Z02. 79- Codify by AAPC.
BACTROBAN ointment is used for the treatment of certain types of skin infections such as school sores (impetigo), infection of the hair root and boils. BACTROBAN is also used when infection occurs in skin damaged by eczema, dermatitis, psoriasis, herpes (cold sores), wounds, cuts, grazes, insect bites, minor burns etc.
Bactroban Ointment belongs to a class of drugs called Antibacterials, Topical.
GENERIC NAME: MUPIROCIN OINTMENT - TOPICAL (mue-PIR-oh-sin)
All such claims must be accompanied by the appropriate ICD-10 code for preoperative examination (i.e., Z01. 810 – Z01. 818).
A preoperative examination to clear the patient for surgery is part of the global surgical package, and should not be reported separately. You should report the appropriate ICD-10 code for preoperative clearance (i.e., Z01. 810 – Z01. 818) and the appropriate ICD-10 code for the condition that prompted surgery.
Other long term (current) drug therapy The 2022 edition of ICD-10-CM Z79. 899 became effective on October 1, 2021. This is the American ICD-10-CM version of Z79.
BACTROBAN (mupirocin) cream is indicated for the topical treatment of secondarily infected traumatic skin lesions such as small lacerations, sutured wounds or abrasions. BACTROBAN (mupirocin) ointment is indicated for the topical treatment of mild impetigo. For Dermatologic Use.
Bactroban is an antibiotic that prevents bacteria from growing on your skin. Bactroban topical (for use on the skin) is used to treat skin infections such as impetigo or a "Staph" infection of the skin.
If your wounds are deep or more severe than minor scratches, cuts, scrapes, and burns, talk to your doctor before using either product. The antibiotic in Bacitracin stops bacterial growth, while the antibiotics in Neosporin stop bacterial growth and also kill existing bacteria.
Each gram of BACTROBAN nasal ointment contains 20 mg (2% w/w) of mupirocin equivalent to 21.5 mg (2 .15% w/w) of mupirocin calcium. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN 649).
BACTROBAN nasal ointment is indicated for the eradication of nasal colonization with methicillin‑resistant Staphylococcus aureus (MRSA) in adult and pediatric patients (aged 12 years and older ) and healthcare workers as part of a comprehensive infection control program to reduce the risk of infection among patients at high risk of MRSA infection during institutional outbreaks of infections with this microorganism.
Press the sides of your nose together and gently rub between your finger and thumb for about 1 minute. This spreads the BACTROBAN nasal ointment around the nose. It is important that you take the full course of BACTROBAN nasal ointment. Do not stop early because the amount of bacteria in your nose may not be reduced.
In a trial conducted in 7 healthy adult male subjects, the elimination half‑life after intravenous administration of mupirocin was 20 to 40 minutes for mupirocin and 30 to 80 minutes for monic acid.
High-level mupirocin resistance (≥512 mcg/mL) may be determined using standard disk diffusion or broth microdilution tests. 1,2 The significance of these results, with regard to decolonization regimens, should be evaluated at each medical facility, in conjunction with laboratory, medical, and infection control staff.
Pediatric Patients: The pharmacokinetic properties of mupirocin following intranasal application of BACTROBAN nasal ointment have not been adequately characterized in neonates or other children younger than 12 years, and in addition, the safety and efficacy of the product in children younger than 12 years have not been established.
The estimated background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.